Pediatric immunotherapy and HIV control

Tehillah T. Chinunga,Ann Chahroudi,Susan P. Ribeiro

DOI: https://doi.org/10.1097/coh.0000000000000857

2024-06-07

Current Opinion in HIV and AIDS

Abstract:The global burden of HIV infection persists and in 2022, out of approximately 39 million people living with HIV (PLWH), 1.5 million were children living with HIV (CLWH) under the age of 15 [1] . An overview of the main areas of focus in this article is illustrated in figure 1. Vertical transmission of HIV is the most common route of infection for children, with high maternal viremia being the strongest predictor of transmission [1,2] . Additional factors such as settings in which there is a higher rate of HIV infections in women of child-bearing age, inadequate access to interventions (e.g., antiretroviral therapy [ART]), and unpredictable timing of ART initiation in pregnancy contribute to vertical transmission of HIV [2,3] . In the absence of ART during pregnancy, the rate of HIV transmission varies from 35% in utero , to 65% intrapartum and 7% to 22% through breastfeeding [4,5] . Without treatment, CLWH demonstrate a greater risk of acquiring opportunistic infections as well as more rapid disease progression compared to adults [3] . Investigating HIV infection in CLWH involves the understanding of the pediatric immune system and how it changes phenotypically and functionally in the neonatal, infant, and childhood periods. Within this framework, HIV pathogenesis, persistence, and host immune responses have been described, although much remains to be learned. Strategies to promote antiviral immune responses against HIV may be particularly beneficial for CLWH who tend to have less robust immunity. However, the type of immunotherapy that provides benefit may be highly age-dependent and HIV-related factors (time of ART initiation in relation to infection, duration of viral suppression, and so on) also influence outcomes. Well controlled studies of the immune system in CLWH, clinical trials of candidate immunotherapies, and descriptions of unique cases of protection inform our understanding of the desired immune features to induce better disease outcomes, reservoir reduction, as well as viral control without ART. Contributing to such scenarios, using pediatric nonhuman primate (NHP) models brings advantages to answer immunological questions as well as to assess the potential of immunotherapeutic interventions in impacting the size of the viral reservoir and/or control of viral rebound in cases of ATI (analytical treatment interruption).

immunology,infectious diseases